BRIEF-Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain

Reuters
05 Feb
BRIEF-Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain

Feb 5 (Reuters) - VistaGen Therapeutics Inc VTGN.O:

  • VISTAGEN RECEIVES U.S. PATENT FOR AV-101 TO TREAT NEUROPATHIC PAIN

  • VISTAGEN THERAPEUTICS-PLANS TO SEEK POTENTIAL STRATEGIC COLLABORATIONS TO FURTHER ADVANCE POTENTIAL CLINICAL DEVELOPMENT, COMMERCIALIZATION OF AV-101

  • VISTAGEN THERAPEUTICS INC - PATENT WILL NOT EXPIRE UNTIL AT LEAST 2034

Source text: ID:nBw3rMzwHa

Further company coverage: VTGN.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10